This result could suggest that KIR3DS1 does not recognize HLA-Bw4 molecules in a physiological setting. The authors emphasize the induced expression of KIR3DS1 observed on

stimulated NK cells and the higher frequency of KIR3DS1+ NK cells in Bw4 individuals. The aim of this study was to investigate the presence of KIR3DS1 and KIR3DL1 receptors and selleck chemical the combination with their ligands HLA-Bw4 (loci A and B alleles) by way of establishing whether they can contribute to protection against HIV infection in highly exposed and persistently seronegative (HESN) partners of individuals infected with HIV-1. Twenty-three HIV-1 serodiscordant heterosexual couples (23 HIV-1– individuals and their 23 HIV-1+ partners), 100 HIV-1+ patients and 200 healthy individual organ donors were included in this retrospective case–control study. Of the 23 HIV-1– people (mean age 36·6 ± 6·9 years), 14 were women and nine were men. Inclusion criteria were: HIV-1– people who had multiple unprotected sex episodes with their HIV-1+ partners, and were HESN to HIV-1 infection for more than 5 years. Rucaparib Nine couples had between one and three children during that period. The HIV+ couples (mean age of 34·9 ± 7·18 years), had been seroconverted for more

than 5 years and they had high viral load at sometime in the 5 years of contact with their partners. They were not included in the group of HIV-1+ patients. A group of one hundred HIV-1+ patients (mean age 32·4 ± 5·8 years) had been seroconverted for more than 8 years, with a history of CD4 counts < 400/ml and high viral load; most received antiretroviral therapy. medroxyprogesterone The individuals included in this study signed the informed consent according to the Helsinki Declaration of 1975.

DNA samples were extracted from mononuclear cells of peripheral blood by using the salting-out or the commercial method (QIAamp DNA Mini kit Qiagen, Valencia, CA) as well. HLA typing was performed in the laboratory before ablation. The control group belongs to the same ethnic background as patients. HLA-A* and HLA-B* typing was performed by means of PCR followed by sequence-specific oligonucleotide probe reverse hybridization (medium-resolution sequence-specific oligonucleotide). The results of the analyses were interpreted using the DYNAL strip software following the hybridization patterns updated twice a year by the manufacturer, according to the WHO Nomenclature Committee and the IMGT / HLA Database. The latest hit table can be found at www.tissue-typing.com. The inhibitory KIR3DL1 and the activating KIR3DS1 were studied by PCR sequence-specific primers (PCR-SSP) as described by Uhrberg et al.,[13] PCR products were electrophoresed on 2% agarose gel to determine the presence of the amplified products (KIR3DS1, 249 bp and KIR3DL1 277 bp). The results of PCR-SSP were previously validated using a commercial Kit [KIR Genotyping SSP KIT; Invitrogen Company (Carlsbad, CA)].